"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 3 | 2 | 5 |
| 2001 | 2 | 5 | 7 |
| 2002 | 2 | 3 | 5 |
| 2003 | 2 | 4 | 6 |
| 2004 | 5 | 8 | 13 |
| 2005 | 3 | 2 | 5 |
| 2006 | 4 | 2 | 6 |
| 2007 | 4 | 1 | 5 |
| 2008 | 7 | 6 | 13 |
| 2009 | 3 | 2 | 5 |
| 2010 | 7 | 5 | 12 |
| 2011 | 5 | 5 | 10 |
| 2012 | 8 | 7 | 15 |
| 2013 | 7 | 9 | 16 |
| 2014 | 6 | 8 | 14 |
| 2015 | 9 | 15 | 24 |
| 2016 | 20 | 2 | 22 |
| 2017 | 22 | 3 | 25 |
| 2018 | 28 | 13 | 41 |
| 2019 | 28 | 16 | 44 |
| 2020 | 19 | 24 | 43 |
| 2021 | 22 | 19 | 41 |
| 2022 | 2 | 25 | 27 |
| 2023 | 1 | 5 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. Clin Cancer Res. 2023 05 01; 29(9):1698-1707.
-
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature. 2023 Mar; 615(7953):697-704.
-
Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity. Biomaterials. 2023 05; 296:122062.
-
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy. Curr Oncol Rep. 2023 03; 25(3):189-199.
-
A Three-in-One Nanoscale Coordination Polymer for Potent Chemo-Immunotherapy. Small Methods. 2023 05; 7(5):e2201437.
-
CD8+ T?cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med. 2023 01 17; 4(1):100878.
-
Treatment of rheumatic adverse events of cancer immunotherapy. Best Pract Res Clin Rheumatol. 2022 Dec; 36(4):101805.
-
Immunotherapy partners after progression: Right place, right time? Cancer. 2023 01 15; 129(2):181-183.
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.
-
Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 06; 165(6):1949-1953.